

# **Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects**



*World Leaders in Health Industry Analysis*



---

**Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects**

August 2008

ISBN: 978-1-85822-327-8

© Copyright 2008 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library.

# CONTENTS

**EXECUTIVE SUMMARY ..... 1**

*Figure 1: Growth in biomarker market 2007-2015 ..... 1*

**What are biomarkers? .....2**

**Why are they important? .....2**

*Figure 2: Potential impact of biomarkers on disease pathways .....2*

**What technologies are involved?.....3**

**What impact will biomarkers have on R&D? .....3**

*Figure 3: Potential impact of biomarkers on R&D.....3*

**Who are the major biomarker players and in what research area? .....4**

**Cancer biomarker companies .....5**

**Cardiovascular biomarker companies.....6**

**CNS biomarkers companies.....7**

**Company Analysis Criteria.....7**

    Biomarker technology & platforms .....7

    Association/clinical studies .....8

    Management strategy .....8

    Application & potential .....8

**CANCER MARKET & REVENUES ..... 9**

**Market revenues - global .....9**

*Figure 1: Global cancer drugs sales (2007) .....9*

**Market revenues – leading brands .....10**

*Figure 2: Leading cancer brands (2007) .....10*

**Market revenues – leading players.....11**

*Figure 3: Top 10 oncology players (2007 revenues) .....11*

**CANCER EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT ..... 12**

**Epidemiology.....12**

*Table 1: Cancer Statistics for four most common cancers, 2008 .....12*

**Diagnosis.....12**

**Screening .....13**

*Table 2: Cancer screening .....13*

**Current & future treatment .....14**

**Future treatment.....14**

*Figure 4: Anticancer drugs in clinical development.....15*

**CANCER BIOMARKERS ..... 16**

**Cancer biomarker R&D.....16**

*Table 3: Types of biomarker.....17*

**Known cancer biomarkers .....17**

*Table 4: Commercially available known cancer biomarker diagnostics .....17*

**Probable and possible valid cancer biomarkers .....18**

*Table 5: Probable cancer biomarkers diagnostics .....19*

*Table 6: Possible cancer biomarkers diagnostics .....19*

**CANCER BIOMARKER OPPORTUNITIES & CHALLENGES..... 21**

**Opportunities .....21**

**Challenges.....21**

**BIOMARKER MARKET ..... 23**

**Biomarker market revenues - global ..... 23**

*Figure 8: Global biomarker sales in 2007 .....23*

**Cancer biomarker market revenues - global ..... 24**

*Figure 9: Global cancer biomarker sales in 2007 .....24*

<b>Future biomarker market revenues – global .....</b>	<b>24</b>
<i>Figure 10: Global biomarker sales in 2015 .....</i>	<i>25</i>
<b>Future cancer biomarker market revenues - global .....</b>	<b>25</b>
<i>Figure 11: Global cancer biomarker sales in 2015 .....</i>	<i>26</i>
<b>CANCER BIOMARKER TRENDS .....</b>	<b>27</b>
<i>Table 7: Recent deals in oncology biomarkers.....</i>	<i>27</i>
<b>Pharma and specialty pharma deals .....</b>	<b>29</b>
<b>Collaborations with service providers .....</b>	<b>29</b>
<b>Collaborations with academics and consortia .....</b>	<b>29</b>
<b>BIOMARKER ANALYSIS .....</b>	<b>30</b>
<b>DNA biomarkers .....</b>	<b>30</b>
<b>RNA and microRNA biomarkers .....</b>	<b>30</b>
<b>Proteomic biomarkers .....</b>	<b>30</b>
<b>KEY BIOMARKER COMPANIES ANALYSED.....</b>	<b>31</b>
<b>KEY BIOMARKER EVALUATION CRITERIA .....</b>	<b>32</b>
<b>CANCER BIOMARKER- COMPANY ANALYSIS .....</b>	<b>33</b>
<b>Abbott Diagnostics.....</b>	<b>33</b>
<b>Biomarker novelty &amp; technology platform.....</b>	<b>33</b>
<i>Figure 12: Abbott’s UroVysion bladder cancer test.....</i>	<i>33</i>
<b>Association studies/clinical data.....</b>	<b>34</b>
<b>Pivotal Trial .....</b>	<b>34</b>
<i>Table 7: Comparison of UroVysion vs Cystoscopy/Histology for Detection of Bladder Cancer Recurrence by Stage and Grade* .....</i>	<i>34</i>
<b>Management strategy .....</b>	<b>34</b>
<b>Application &amp; market potential .....</b>	<b>34</b>
<b>Biomarker analysis .....</b>	<b>35</b>
<b>Affymetrix .....</b>	<b>36</b>
<b>Biomarker novelty &amp; technology platform.....</b>	<b>36</b>
<i>Figure 13: Affymetrix’ approach to biomarker discovery, validation and clinical utility applications.....</i>	<i>36</i>
<b>Association studies/clinical data.....</b>	<b>37</b>
<b>Management strategy .....</b>	<b>37</b>
<b>Application &amp; market potential .....</b>	<b>37</b>
<b>Biomarker analysis .....</b>	<b>37</b>
<b>Agendia BV.....</b>	<b>39</b>
<b>Biomarker novelty &amp; technology platform.....</b>	<b>39</b>
<b>Association studies/clinical data.....</b>	<b>39</b>
<i>Figure 14: MammaPrint Profile vs NIH Consensus Criteria.....</i>	<i>39</i>
<b>Management strategy .....</b>	<b>40</b>
<b>Application &amp; market potential .....</b>	<b>40</b>
<b>Biomarker analysis .....</b>	<b>40</b>
<b>AltheaDx.....</b>	<b>41</b>
<b>Biomarker novelty &amp; technology platform.....</b>	<b>41</b>
<b>Association studies/clinical data.....</b>	<b>41</b>
<b>Management strategy .....</b>	<b>41</b>
<b>Application &amp; market potential .....</b>	<b>41</b>
<b>Biomarker analysis .....</b>	<b>41</b>
<b>AVEO Pharmaceuticals.....</b>	<b>43</b>
<b>Biomarker novelty &amp; technology platform.....</b>	<b>43</b>
<b>Association studies/clinical data.....</b>	<b>43</b>
<b>Management strategy .....</b>	<b>43</b>
<b>Application &amp; market potential .....</b>	<b>43</b>
<b>Biomarker analysis .....</b>	<b>44</b>

AviaraDx ..... 45

**Biomarker novelty & technology platform**..... 45

**Association studies/clinical data**..... 45

**Management strategy** ..... 45

**Application & market potential** ..... 46

**Biomarker analysis**..... 46

BG Medicine..... 47

**Biomarker novelty & technology platform**.....47

**Association studies/clinical data**.....47

**Management strategy** .....47

*Figure 15: BG Medicines Biomarker Programme* .....48

**Application & market potential** ..... 48

**Biomarker analysis**..... 48

Beckman Coulter ..... 50

**Biomarker novelty & technology platform**..... 50

**Association studies/clinical data**..... 50

**Management strategy** ..... 50

**Application & market potential** .....51

**Biomarker analysis**.....51

BioCurex ..... 52

**Biomarker novelty & technology platform**.....52

**Association studies/clinical data**.....52

**Management strategy** .....52

**Application & market potential** .....53

**Biomarker analysis**.....53

Biomedical Diagnostics ..... 54

**Biomarker novelty & technology platform**..... 54

**Association studies/clinical data**..... 54

**Management strategy** ..... 54

**Application & market potential** ..... 54

**Biomarker analysis**.....55

Biomerica ..... 56

**Biomarker novelty & technology platform**..... 56

**Association studies/clinical data**..... 56

**Management strategy** ..... 56

**Application & market potential** ..... 56

**Biomarker analysis**.....57

Bruker Daltonics..... 58

**Biomarker novelty & technology platform**..... 58

**Association studies/clinical data**..... 58

**Management strategy** ..... 58

**Application & market potential** ..... 58

**Biomarker analysis**..... 58

Caprion Proteomics..... 60

**Biomarker novelty & technology platform**..... 60

**Association studies/clinical data**..... 60

**Management strategy** ..... 60

**Application & market potential** ..... 60

**Biomarker analysis**..... 60

Clinical Data ..... 62

**Biomarker novelty & technology platform**..... 62

Association studies/clinical data.....	62
Management strategy .....	62
Application & market potential .....	62
Biomarker analysis .....	63
Celera .....	64
Biomarker novelty & technology platform.....	64
Association studies/clinical data.....	64
Management strategy .....	64
Application & market potential .....	65
Biomarker analysis .....	65
Dako Denmark A/S .....	66
Biomarker novelty & technology platform.....	66
Association studies/clinical data.....	66
Management strategy .....	66
Application & market potential .....	66
Biomarker analysis .....	67
DxS Ltd.....	68
Biomarker novelty & technology platform.....	68
Association studies/clinical data.....	68
Management strategy .....	68
Application & market potential .....	68
Biomarker analysis .....	69
Epigenomics AG .....	70
Biomarker novelty & technology platform.....	70
Association studies/clinical data.....	70
Management strategy .....	70
Application & market potential .....	71
Biomarker analysis .....	71
Epistem Plc.....	72
Biomarker novelty & technology platform.....	72
<i>Figure 16: Epistem's Biomarker Drug Development Programme .....</i>	<i>72</i>
Association studies/clinical data.....	73
Management strategy .....	73
Application & market potential .....	73
Biomarker analysis .....	73
GeneNews .....	75
Biomarker novelty & technology platform.....	75
<i>Figure 17: GeneNews' Sentinel Principle .....</i>	<i>75</i>
Association studies/clinical data.....	76
Management strategy .....	76
Application & market potential .....	76
Biomarker analysis .....	76
Fujirebio Diagnostics, Inc .....	78
Biomarker novelty & technology platform.....	78
Association studies/clinical data.....	78
Management strategy .....	78
Application & market potential .....	79
Biomarker analysis .....	79
Genomic Health .....	80
Biomarker novelty & technology platform.....	80
<i>Figure 18: Oncotype Dx test for invasive breast cancer .....</i>	<i>80</i>

**Association studies/clinical data**..... 80

**Management strategy** .....81

**Application & market potential** .....81

**Biomarker analysis**.....81

**Gen-Probe**..... 83

**Biomarker novelty & technology platform**..... 83

**Association studies/clinical data**..... 83

**Management strategy** ..... 83

**Application & market potential** ..... 84

**Biomarker analysis**..... 84

**Genzyme Genetics**..... 85

**Biomarker novelty & technology platform**..... 85

**Association studies/clinical data**..... 85

**Management strategy** ..... 85

**Application & market potential** ..... 85

**Biomarker analysis**..... 86

**InterGenetics** ..... 87

**Biomarker novelty & technology platform**..... 87

**Association studies/clinical data**..... 87

**Management strategy** ..... 87

**Application & market potential** ..... 87

**Biomarker analysis**..... 88

**Ipsogen Therapeutics** ..... 89

**Biomarker novelty & technology platform**..... 89

**Association studies/clinical data**..... 89

**Management strategy** ..... 89

*Figure 19: Oncotype Dx test for invasive breast cancer* .....90

**Application & market potential** ..... 90

**Biomarker analysis**..... 90

**Laboratory Corporation of America** ..... 91

**Biomarker novelty & technology platform**.....91

**Association studies/clinical data**.....91

**Management strategy** .....91

**Application & market potential** .....91

**Biomarker analysis**.....91

**Matritech** ..... 93

**Biomarker novelty & technology platform**..... 93

**Association studies/clinical data**..... 93

**Management strategy** ..... 93

**Application & market potential** ..... 93

**Biomarker analysis**..... 94

**Monogram Biosciences** ..... 95

**Biomarker novelty & technology platform**..... 95

*Figure 20: VeraTag Assay*.....95

**Association studies/clinical data**..... 95

*Figure 21: VeraTag Clinical Data: Bordet Cohort*.....96

**Management strategy** ..... 96

**Application & market potential** ..... 96

**Biomarker analysis**..... 97

**Orion Genomics** ..... 98

**Biomarker novelty & technology platform**..... 98

<i>Figure 22: Orion's MethylScope</i> .....	98
<b>Association studies/clinical data</b> .....	<b>98</b>
<b>Management strategy</b> .....	<b>99</b>
<b>Application &amp; market potential</b> .....	<b>99</b>
<b>Biomarker analysis</b> .....	<b>99</b>
<b>Oxford Genome Biosciences (UK) Ltd</b> .....	<b>100</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>100</b>
<b>Association studies/clinical data</b> .....	<b>100</b>
<b>Management strategy</b> .....	<b>100</b>
<b>Application &amp; market potential</b> .....	<b>100</b>
<b>Biomarker analysis</b> .....	<b>101</b>
<b>Power3 Medical Products</b> .....	<b>102</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>102</b>
<b>Association studies/clinical data</b> .....	<b>102</b>
<b>Management strategy</b> .....	<b>102</b>
<i>Figure 23: Powder3's business strategy</i> .....	103
<b>Application &amp; market potential</b> .....	<b>103</b>
<b>Biomarker analysis</b> .....	<b>103</b>
<b>Predictive Biosciences</b> .....	<b>105</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>105</b>
<b>Association studies/clinical data</b> .....	<b>105</b>
<b>Management strategy</b> .....	<b>105</b>
<b>Application &amp; market potential</b> .....	<b>105</b>
<b>Biomarker analysis</b> .....	<b>106</b>
<b>Provista Life Sciences</b> .....	<b>107</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>107</b>
<b>Association studies/clinical data</b> .....	<b>107</b>
<b>Management strategy</b> .....	<b>107</b>
<b>Application &amp; market potential</b> .....	<b>108</b>
<b>Biomarker analysis</b> .....	<b>108</b>
<b>Quest Diagnostics</b> .....	<b>109</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>109</b>
<b>Association studies/clinical data</b> .....	<b>109</b>
<b>Management strategy</b> .....	<b>109</b>
<b>Application &amp; market potential</b> .....	<b>109</b>
<b>Biomarker analysis</b> .....	<b>110</b>
<b>Roche Diagnostics</b> .....	<b>111</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>111</b>
<i>Figure 24: Diagnostic marker candidate to a product</i> .....	111
<b>Association studies/clinical data</b> .....	<b>112</b>
<i>Figure 25: Biomarkers distinguish Leukaemia subclasses</i> .....	112
<b>Management strategy</b> .....	<b>112</b>
<b>Application &amp; market potential</b> .....	<b>113</b>
<b>Biomarker analysis</b> .....	<b>113</b>
<b>SuperArray Bioscience Corporation</b> .....	<b>114</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>114</b>
<b>Association studies/clinical data</b> .....	<b>114</b>
<b>Management strategy</b> .....	<b>114</b>
<b>Application &amp; market potential</b> .....	<b>114</b>
<b>Biomarker analysis</b> .....	<b>114</b>
<b>Third Wave Technologies</b> .....	<b>116</b>

**Biomarker novelty & technology platform**..... 116  
**Association studies/clinical data**..... 116  
**Management strategy** ..... 116  
**Application & market potential** ..... 116  
**Biomarker analysis**..... 117  
**Upstream Biosciences**..... 118  
**Biomarker novelty & technology platform**..... 118  
**Association studies/clinical data**..... 118  
**Management strategy** ..... 118  
**Application & market potential** ..... 118  
**Biomarker analysis**..... 119  
**Veridex, LLC** ..... 120  
**Biomarker novelty & technology platform**..... 120  
**Association studies/clinical data**..... 120  
**Management strategy** ..... 120  
**Application & market potential** ..... 121  
**Biomarker analysis**..... 121  
**Vermillion**..... 122  
**Biomarker novelty & technology platform**..... 122  
**Association studies/clinical data**..... 122  
**Management strategy** ..... 122  
**Application & market potential** ..... 123  
**Biomarker analysis**..... 123  
**CANCER BIOMARKER APPENDIX 1** ..... 124  
*Table 8: Global biomarker sales 2007-20015E* ..... 124  
**CANCER BIOMARKER APPENDIX 2** ..... 125  
*Table 8: Global cancer biomarker sales 2007-20015E*..... 125  
**CANCER BIOMARKER APPENDIX 3**..... 126  
**Company Analysis Criteria** ..... 126  
**Biomarker technology & platforms** ..... 126  
**Association studies** ..... 126  
**Management strategy** ..... 126  
**Application & potential**..... 126  
*Table 9: Key cancer biomarker companies*..... 128  
*Figure 26: Leading Cancer Biomarker Companies – Service providers, Technology Providers, Biomarker Discovery & Diagnostic Developers*..... 130  
**GLOSSARY** ..... 131  
**ACRONYMS**..... 133  
**BIBLIOGRAPHY & ENDNOTES**..... 138  
**CNS MARKET & REVENUES** ..... 139  
**Market revenues - global** ..... 139  
*Figure 1: Global CNS drugs sales (2007)* ..... 139  
**Market revenues – leading brands** ..... 140  
*Figure 2: Leading CNS brands (2007)* ..... 140  
**Market revenues – leading players**..... 141  
*Figure 3: Top 10 CNS players (2007 revenues)* ..... 141  
**CNS EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT** ..... 142  
**Epidemiology**..... 142  
*Table 1: CNS statistics for the most common CNS disorders, 2008*..... 142  
**Diagnosis**..... 142  
*Table 2: Indication for CT and MRI in the CNS*..... 143  
**Screening** ..... 143

<b>Current &amp; future treatment</b> .....	<b>143</b>
<i>Table 3: Classes of CNS drugs approved for acute and chronic conditions</i> .....	144
<b>Future treatment</b> .....	<b>144</b>
<i>Figure 4: CNS drugs in clinical development</i> .....	144
<b>CNS BIOMARKERS</b> .....	<b>145</b>
<b>CNS biomarker R&amp;D</b> .....	<b>145</b>
<i>Figure 5: Imaging biomarkers as surrogate endpoints</i> .....	146
<i>Table 4: Types of biomarker</i> .....	146
<b>Known CNS biomarkers</b> .....	<b>147</b>
<i>Table 5: Commercially available known CNS biomarker diagnostics</i> .....	147
<b>Probable and possible valid CNS biomarkers</b> .....	<b>147</b>
<i>Table 6: Probable CNS biomarkers diagnostics</i> .....	148
<i>Table 7: Possible CNS biomarkers diagnostics</i> .....	148
<b>CNS BIOMARKER OPPORTUNITIES &amp; CHALLENGES</b> .....	<b>152</b>
<b>Opportunities</b> .....	<b>152</b>
<i>Figure 7: CNS biomarker opportunities</i> .....	152
<b>Challenges</b> .....	<b>153</b>
<i>Figure 8: CNS biomarker challenges</i> .....	153
<b>BIOMARKER MARKET</b> .....	<b>155</b>
<b>Biomarker market revenues - global</b> .....	<b>155</b>
<i>Figure 9: Global biomarker sales in 2007</i> .....	155
<b>CNS biomarker market revenues - global</b> .....	<b>156</b>
<i>Figure 10: Global CNS biomarker sales in 2007</i> .....	156
<b>Future biomarker market revenues – global</b> .....	<b>156</b>
<i>Figure 11: Global biomarker sales in 2015</i> .....	157
<b>Future CNS biomarker market revenues - global</b> .....	<b>157</b>
<i>Figure 12: Global CNS biomarker sales in 2015</i> .....	158
<b>CNS BIOMARKER TRENDS</b> .....	<b>159</b>
<i>Table 8: Recent deals in the oncology biomarkers</i> .....	159
<b>Pharma deals</b> .....	<b>160</b>
<b>Collaborations with CNS discovery companies</b> .....	<b>160</b>
<b>Collaborations with academics and consortia</b> .....	<b>160</b>
<b>BIOMARKER ANALYSIS</b> .....	<b>162</b>
<b>DNA biomarkers</b> .....	<b>162</b>
<b>Proteomic biomarkers</b> .....	<b>162</b>
<b>Metabolomic biomarkers</b> .....	<b>162</b>
<b>Electrophysiology biomarkers</b> .....	<b>162</b>
<b>Imaging biomarkers</b> .....	<b>162</b>
<b>KEY BIOMARKER COMPANIES ANALYSED</b> .....	<b>163</b>
<b>KEY BIOMARKER EVALUATION CRITERIA</b> .....	<b>164</b>
<b>CNS BIOMARKER- COMPANY ANALYSIS</b> .....	<b>165</b>
<b>Affymetrix</b> .....	<b>165</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>165</b>
<b>Association studies/clinical data</b> .....	<b>165</b>
<b>Management strategy</b> .....	<b>165</b>
<b>Application &amp; market potential</b> .....	<b>166</b>
<b>Biomarker analysis</b> .....	<b>166</b>
<b>Applied NeuroSolutions</b> .....	<b>167</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>167</b>
<b>Association studies/clinical data</b> .....	<b>167</b>
<b>Management strategy</b> .....	<b>167</b>

**Application & market potential .....167**  
**Biomarker analysis ..... 168**  
**Banyan Biomarkers ..... 169**  
**Biomarker novelty & technology platform..... 169**  
*Figure 14: Source Of Banyans TNI biomarkers ..... 169*  
**Association studies/clinical data..... 169**  
**Management strategy ..... 169**  
**Application & market potential ..... 169**  
**Biomarker analysis .....170**  
**BG Medicine..... 171**  
**Biomarker novelty & technology platform.....171**  
**Association studies/clinical data.....171**  
**Management strategy .....171**  
**Application & market potential .....172**  
**Biomarker analysis .....172**  
**Biosite, Inc ..... 173**  
**Biomarker novelty & technology platform.....173**  
**Association studies/clinical data.....173**  
**Management strategy .....173**  
**Application & market potential .....174**  
**Biomarker analysis .....174**  
**Biospective..... 175**  
**Biomarker novelty & technology platform.....175**  
**Association studies/clinical data.....175**  
**Management strategy .....175**  
**Application & market potential .....175**  
**Biomarker analysis .....176**  
**Celera, Inc..... 177**  
**Biomarker novelty & technology platform.....177**  
**Association studies/clinical data.....177**  
**Management strategy .....177**  
**Application & market potential .....177**  
**Biomarker analysis .....178**  
**Clinical Data Inc..... 179**  
**Biomarker novelty & technology platform.....179**  
**Association studies/clinical data.....179**  
**Management strategy ..... 180**  
**Application & market potential ..... 180**  
**Biomarker analysis ..... 180**  
**Curidium Medica..... 181**  
**Biomarker novelty & technology platform.....181**  
**Association studies/clinical data.....181**  
*Figure 17: Curidium’s PsychINDx test for schizophrenia/bipolar disorder..... 181*  
**Management strategy ..... 182**  
**Application & market potential ..... 182**  
**Digilab Peptidomics ..... 183**  
**Biomarker novelty & technology platform..... 183**  
**Association studies/clinical data..... 183**  
**Management strategy ..... 183**  
**Application & market potential ..... 183**  
**Biomarker analysis ..... 184**

EnVivo Pharmaceuticals .....	185
<b>Biomarker novelty &amp; technology platform</b> .....	185
<b>Association studies/clinical data</b> .....	185
<b>Management strategy</b> .....	185
<b>Application &amp; market potential</b> .....	185
<b>Biomarker analysis</b> .....	186
Innogenetics NV .....	187
<b>Biomarker novelty &amp; technology platform</b> .....	187
<i>Figure 18: Innogenetic multiparameter analysis</i> .....	187
<b>Association studies/clinical data</b> .....	187
<b>Management strategy</b> .....	187
<b>Application &amp; market potential</b> .....	188
<b>Biomarker analysis</b> .....	188
KineMed, Inc.....	189
<b>Biomarker novelty &amp; technology platform</b> .....	189
<i>Figure 19: KineMarker technology platform</i> .....	189
<b>Association studies/clinical data</b> .....	190
<b>Management strategy</b> .....	190
<b>Application &amp; market potential</b> .....	190
<b>Biomarker analysis</b> .....	190
Lipomics Technologies .....	191
<b>Biomarker novelty &amp; technology platform</b> .....	191
<b>Association studies/clinical data</b> .....	191
<b>Management strategy</b> .....	191
<b>Application &amp; market potential</b> .....	191
<b>Biomarker analysis</b> .....	192
Luminex Corporation .....	193
<b>Biomarker novelty &amp; technology platform</b> .....	193
<b>Association studies/clinical data</b> .....	193
<b>Management strategy</b> .....	193
<i>Figure 20: Luminex is capturing end-user market share</i> .....	194
<b>Application &amp; market potential</b> .....	194
<b>Biomarker analysis</b> .....	194
Memory Pharmaceuticals Corporation .....	195
<b>Biomarker novelty &amp; technology platform</b> .....	195
<b>Association studies/clinical data</b> .....	195
<b>Management strategy</b> .....	195
<b>Application &amp; market potential</b> .....	195
<b>Biomarker analysis</b> .....	196
Metabolon, Inc .....	197
<b>Biomarker novelty &amp; technology platform</b> .....	197
<i>Figure 21: Metabolon integrated analytic platform</i> .....	197
<b>Association studies/clinical data</b> .....	197
<b>Management strategy</b> .....	198
<b>Application &amp; market potential</b> .....	198
<b>Biomarker analysis</b> .....	198
Nanogen, Inc .....	199
<b>Biomarker novelty &amp; technology platform</b> .....	199
<b>Association studies/clinical data</b> .....	199
<b>Management strategy</b> .....	199
<b>Application &amp; market potential</b> .....	199

**Biomarker analysis** ..... 200

**Nanosphere, Inc.** ..... 201

**Biomarker novelty & technology platform**..... 201

*Figure 22. Nanosphere's gold nanoparticle technology* .....201

**Association studies/clinical data**..... 202

**Management strategy** ..... 202

**Application & market potential** ..... 202

**Biomarker analysis**..... 202

**Nymox Pharmaceutical** ..... 203

**Biomarker novelty & technology platform**..... 203

**Association studies/clinical data**..... 203

**Management strategy** ..... 203

**Application & market potential** ..... 203

**Biomarker analysis**..... 204

*Competitor Ratio Analysis Score = 12/40* .....204

**Osta Biotechnologies** ..... 205

**Biomarker novelty & technology platform**..... 205

**Association studies/clinical data**..... 205

**Management strategy** ..... 205

**Application & market potential** ..... 205

**Biomarker analysis**..... 206

**Phenomenome Discoveries, Inc.**..... 207

**Biomarker novelty & technology platform**..... 207

**Association studies/clinical data**..... 207

**Management strategy** ..... 207

**Application & market potential** ..... 207

**Biomarker analysis**..... 208

**PPD, Inc** ..... 209

**Biomarker novelty & technology platform**..... 209

**Association studies/clinical data**..... 209

**Management strategy** ..... 209

**Application & market potential** ..... 209

**Biomarker analysis**..... 210

*Competitor Ratio Analysis Score = 16/40* ..... 210

**Power3 Medical Products**..... 211

**Biomarker novelty & technology platform**.....211

**Association studies/clinical data**.....211

**Management strategy** .....211

**Application & market potential** .....211

**Biomarker analysis** .....212

**Provista Life Sciences** ..... 213

**Biomarker novelty & technology platform**.....213

**Association studies/clinical data**.....213

**Management strategy** .....213

**Application & market potential** .....213

**Biomarker analysis** .....214

**Psynova Neurotech Ltd**..... 215

**Biomarker novelty & technology platform**.....215

**Association studies/clinical data**.....215

*Figure 23: Two proteins identified in CSF are also biomarkers in serum* ..... 215

**Management strategy** .....216

<b>Application &amp; market potential</b> .....	<b>216</b>
<b>Biomarker analysis</b> .....	<b>216</b>
<b>Satoris, Inc</b> .....	<b>217</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>217</b>
<b>Association studies/clinical data</b> .....	<b>217</b>
<i>Figure 24: Early identification of Alzheimer's disease in at-risk MCI patients</i> .....	217
<b>Management strategy</b> .....	<b>218</b>
<b>Application &amp; market potential</b> .....	<b>218</b>
<b>Biomarker analysis</b> .....	<b>218</b>
<b>Siemens Medical Solutions</b> .....	<b>219</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>219</b>
<i>Figure 25: Siemens Integrated in vivo &amp; in vitro diagnostic suites</i> .....	219
<b>Association studies/clinical data</b> .....	<b>219</b>
<b>Management strategy</b> .....	<b>220</b>
<b>Application &amp; market potential</b> .....	<b>220</b>
<b>Biomarker analysis</b> .....	<b>220</b>
<i>Competitor Ratio Analysis Score = 20/40</i> .....	220
<b>SuperArray Bioscience Corporation</b> .....	<b>222</b>
<b>Biomarker novelty &amp; technology platform</b> .....	<b>222</b>
<b>Association studies/clinical data</b> .....	<b>222</b>
<b>Management strategy</b> .....	<b>222</b>
<b>Application &amp; market potential</b> .....	<b>222</b>
<b>Biomarker analysis</b> .....	<b>223</b>
<b>CNS BIOMARKER APPENDIX 1</b> .....	<b>224</b>
<i>Table 9: Global biomarker sales 2007-20015E</i> .....	224
<b>CNS BIOMARKER APPENDIX 2</b> .....	<b>225</b>
<i>Table 10: Global CNS biomarker sales 2007-20015E</i> .....	225
<b>CNS BIOMARKER APPENDIX 3</b> .....	<b>226</b>
<b>Company Analysis Criteria</b> .....	<b>226</b>
<b>Biomarker technology &amp; platforms</b> .....	<b>226</b>
<b>Association studies</b> .....	<b>226</b>
<b>Management strategy</b> .....	<b>226</b>
<b>Application &amp; potential</b> .....	<b>226</b>
<i>Table 9: Key CNS Biomarker Companies</i> .....	227
<i>Figure 26: Leading CNS Biomarker Companies – Service Providers, Technology Providers, Biomarker Discovery &amp; Diagnostic Developers</i> .....	228
<b>GLOSSARY</b> .....	<b>229</b>
<b>ACRONYMS</b> .....	<b>234</b>
<b>BIBLIOGRAPHY</b> .....	<b>239</b>
<b>CARDIOVASCULAR MARKET &amp; REVENUES</b> .....	<b>241</b>
<b>Market revenues - global</b> .....	<b>241</b>
<i>Figure 1: Global cardiovascular disease drug sales 2007</i> .....	241
<b>Market revenues – leading brands</b> .....	<b>242</b>
<i>Figure 2: Leading Cardiovascular brands (2007)</i> .....	242
<b>Market revenues – leading players</b> .....	<b>243</b>
<i>Figure 3: Top 10 cardiovascular players (2007 revenues)</i> .....	243
<b>CARDIOVASCULAR EPIDEMIOLOGY, DIAGNOSIS, SCREENING &amp; TREATMENT</b> .....	<b>244</b>
<b>Epidemiology</b> .....	<b>244</b>
<i>Figure 4: Breakdown of deaths from cardiovascular diseases in the US (2004)</i> .....	245
<b>Diagnosis</b> .....	<b>245</b>
<b>Screening</b> .....	<b>246</b>
<i>Table 1: Screening for cardiovascular disease</i> .....	246

<b>Current treatments .....</b>	<b>246</b>
<i>Table 2: Cardiovascular therapeutic drug categories and their indications .....</i>	<i>247</i>
<b>Future treatments .....</b>	<b>247</b>
<i>Figure 5: Drugs in clinical development for heart disease.....</i>	<i>248</i>
<b>CARDIOVASCULAR BIOMARKERS .....</b>	<b>249</b>
<b>Cardiovascular biomarker R&amp;D .....</b>	<b>249</b>
<i>Figure 6: Impact of biomarkers on the drug R&amp;D process.....</i>	<i>250</i>
<i>Table 3: Types of biomarker.....</i>	<i>251</i>
<b>Known cardiovascular biomarkers .....</b>	<b>251</b>
<i>Table 4: Commercially available cardiovascular diagnostics.....</i>	<i>251</i>
<b>Probable and possible valid cardiovascular biomarkers.....</b>	<b>253</b>
<i>Table 5: Probable cardiovascular biomarkers .....</i>	<i>254</i>
<i>Table 6: Possible cardiovascular biomarkers .....</i>	<i>255</i>
<b>CARDIOVASCULAR BIOMARKER OPPORTUNITIES &amp; CHALLENGES.....</b>	<b>258</b>
<b>Opportunities .....</b>	<b>258</b>
<i>Figure 7: Cardiovascular biomarker opportunities .....</i>	<i>258</i>
<b>Challenges.....</b>	<b>259</b>
<i>Figure 8: Cardiovascular biomarker challenges .....</i>	<i>259</i>
<b>BIOMARKER MARKET .....</b>	<b>261</b>
<b>Biomarker market revenues – global .....</b>	<b>261</b>
<i>Figure 9: Global biomarker sales in 2007.....</i>	<i>261</i>
<b>Cardiovascular biomarker market revenues – global .....</b>	<b>262</b>
<i>Figure 10: Global cardiovascular biomarker sales in 2007 .....</i>	<i>262</i>
<b>Future biomarker market revenues – global .....</b>	<b>262</b>
<i>Figure 11: Global biomarker sales in 2015.....</i>	<i>263</i>
<b>Future cardiovascular biomarker market revenues – global .....</b>	<b>263</b>
<i>Figure 12: Global cardiovascular biomarker sales in 2015.....</i>	<i>263</i>
<b>CARDIOVASCULAR BIOMARKER TRENDS .....</b>	<b>264</b>
<i>Table 7: Recent deals in cardiovascular biomarkers.....</i>	<i>264</i>
<b>Pharma and specialty pharma deals .....</b>	<b>265</b>
<b>Collaborations with service providers .....</b>	<b>265</b>
<b>Collaborations with academics and consortia .....</b>	<b>265</b>
<b>BIOMARKER ANALYSIS.....</b>	<b>266</b>
<b>Assays for circulating biomarkers.....</b>	<b>266</b>
<b>DNA and RNA biomarkers.....</b>	<b>266</b>
<b>Proteomic, metabolomic biomarkers .....</b>	<b>266</b>
<b>Systems biology for biomarker discovery.....</b>	<b>266</b>
<b>Imaging biomarkers.....</b>	<b>267</b>
<b>KEY BIOMARKER COMPANIES ANALYSED.....</b>	<b>268</b>
<b>KEY BIOMARKER EVALUATION CRITERIA .....</b>	<b>269</b>
<b>CARDIOVASCULAR BIOMARKERS - COMPANY ANALYSIS.....</b>	<b>270</b>
<b>Abbott Diagnostics .....</b>	<b>270</b>
<b>Biomarker novelty &amp; technology platform.....</b>	<b>270</b>
<b>Association studies/clinical data.....</b>	<b>270</b>
<b>Management strategy .....</b>	<b>270</b>
<b>Application &amp; market potential .....</b>	<b>270</b>
<b>Biomarker analysis.....</b>	<b>271</b>
<b>Atherotech .....</b>	<b>272</b>
<b>Biomarker novelty &amp; technology platform.....</b>	<b>272</b>
<b>Association studies/clinical data.....</b>	<b>272</b>
<b>Management strategy .....</b>	<b>272</b>

<b>Application &amp; market potential</b> .....	272
<b>Biomarker analysis</b> .....	272
<b>Affymetrix</b> .....	273
<b>Biomarker novelty &amp; technology platform</b> .....	273
<i>Figure 13: Affymetrix' approach to biomarker discovery, validation and clinical utility applications</i> .....	273
<b>Association studies/clinical data</b> .....	273
<b>Management strategy</b> .....	274
<b>Application &amp; market potential</b> .....	274
<b>Biomarker analysis</b> .....	275
<b>Beckman Coulter</b> .....	276
<b>Biomarker novelty &amp; technology platform</b> .....	276
<b>Association studies/clinical data</b> .....	276
<b>Management strategy</b> .....	276
<b>Application &amp; market potential</b> .....	277
<b>Biomarker analysis</b> .....	277
<b>Berkeley HeartLab</b> .....	278
<b>Biomarker novelty &amp; technology platform</b> .....	278
<i>Figure 14: Markers of cardiovascular disease measured at Berkeley HeartLab</i> .....	278
<b>Association studies/clinical data</b> .....	278
<b>Management strategy</b> .....	279
<b>Application &amp; market potential</b> .....	279
<b>Biomarker analysis</b> .....	279
<b>BG Medicine</b> .....	280
<b>Biomarker novelty &amp; technology platform</b> .....	280
<b>Association studies/clinical data</b> .....	280
<b>Management strategy</b> .....	280
<i>Figure 15: BG Medicine's Biomarker Programme</i> .....	281
<b>Application &amp; market potential</b> .....	281
<b>Biomarker analysis</b> .....	282
<b>CardioDx</b> .....	283
<b>Biomarker novelty &amp; technology platform</b> .....	283
<b>Association studies/clinical data</b> .....	283
<b>Management strategy</b> .....	283
<b>Application &amp; market potential</b> .....	283
<b>Biomarker analysis</b> .....	284
<i>Competitor Ratio Analysis Score = 9/40</i> .....	284
<b>Celera</b> .....	285
<b>Biomarker novelty &amp; technology platform</b> .....	285
<b>Association studies/clinical data</b> .....	285
<b>Management strategy</b> .....	286
<b>Application &amp; market potential</b> .....	286
<b>Biomarker analysis</b> .....	286
<b>CIS Biotech</b> .....	287
<b>Biomarker novelty &amp; technology platform</b> .....	287
<b>Association studies/clinical data</b> .....	287
<b>Management strategy</b> .....	287
<b>Application &amp; market potential</b> .....	287
<b>Biomarker analysis</b> .....	288
<b>Clinical Data</b> .....	289
<b>Biomarker novelty &amp; technology platform</b> .....	289
<b>Association studies/clinical data</b> .....	289

Management strategy .....	290
Application & market potential .....	290
Biomarker analysis .....	290
Compugen .....	291
Biomarker novelty & technology platform.....	291
Association studies/clinical data.....	291
Management strategy .....	291
Application & market potential .....	292
Biomarker analysis .....	292
Critical Diagnostics .....	293
Biomarker novelty & technology platform.....	293
Association studies/clinical data.....	293
Management strategy .....	293
Application & market potential .....	293
Biomarker analysis .....	294
deCODE Genetics .....	295
Biomarker novelty & technology platform.....	295
Association studies/clinical data.....	295
Management strategy .....	295
<i>Figure 16: deCODE's approach to target discovery and development.....</i>	<i>296</i>
Application & market potential .....	296
Biomarker analysis .....	296
diaDexus.....	297
Biomarker novelty & technology platform.....	297
Association studies/clinical data.....	297
Management strategy .....	297
Application & market potential .....	297
Biomarker analysis .....	298
Entelos .....	299
Biomarker novelty & technology platform.....	299
Association studies/clinical data.....	299
Management strategy .....	299
Application & market potential .....	299
Biomarker analysis .....	300
FoxHollow Technologies .....	301
Biomarker novelty & technology platform.....	301
Association studies/clinical data.....	301
Management strategy .....	301
Application & market potential .....	301
Biomarker analysis .....	302
GE Healthcare .....	303
Biomarker novelty & technology platform.....	303
<i>Figure 17: Cardiology focus at GE Healthcare .....</i>	<i>303</i>
Association studies/clinical data.....	304
Management strategy .....	304
Application & market potential .....	304
Biomarker analysis .....	304
Genomas .....	305
Biomarker novelty & technology platform.....	305
<i>Figure 18: PhysioGenomics Technology from Genomas.....</i>	<i>305</i>
Association studies/clinical data.....	305

Management strategy .....	306
Application & market potential .....	306
Biomarker analysis .....	306
Inverness Medical Innovations.....	307
Biomarker novelty & technology platform.....	307
Association studies/clinical data.....	307
Management strategy .....	307
Application & market potential .....	308
Biomarker analysis .....	308
Jurilab .....	309
Biomarker novelty & technology platform.....	309
<i>Figure 19: Jurilab's Genetic Discovery Method .....</i>	<i>310</i>
Association studies/clinical data.....	310
Management strategy .....	311
Application & market potential .....	311
Biomarker analysis .....	311
<i>Competitor Ratio Analysis Score = 12/40 .....</i>	<i>311</i>
Laboratory Corporation of America .....	312
Biomarker novelty & technology platform.....	312
Association studies/clinical data.....	312
Management strategy .....	312
Application & market potential .....	312
Biomarker analysis .....	313
Lipomics Technologies .....	314
Biomarker novelty & technology platform.....	314
Association studies/clinical data.....	314
Management strategy .....	314
Application & market potential .....	314
Biomarker analysis .....	315
LipoScience .....	316
Biomarker novelty & technology platform.....	316
Association studies/clinical data.....	316
Management strategy .....	316
Application & market potential .....	316
Biomarker analysis .....	317
<i>Competitor Ratio Analysis Score = 15/40 .....</i>	<i>317</i>
Nanosphere Inc. ....	318
Biomarker novelty & technology platform.....	318
Association studies/clinical data.....	318
Management strategy .....	318
Application & market potential .....	318
Biomarker analysis .....	319
Osmetech Molecular Diagnostics .....	320
Biomarker novelty & technology platform.....	320
Association studies/clinical data.....	320
Management strategy .....	320
Application & market potential .....	320
Biomarker analysis .....	321
<i>Competitor Ratio Analysis Score = 12/40 .....</i>	<i>321</i>
PrognostiX .....	322
Biomarker novelty & technology platform.....	322

<b>Association studies/clinical data</b> .....	322
<b>Management strategy</b> .....	322
<b>Application &amp; market potential</b> .....	322
<b>Biomarker analysis</b> .....	322
<b>Quest Diagnostics</b> .....	323
<b>Biomarker novelty &amp; technology platform</b> .....	323
<b>Association studies/clinical data</b> .....	323
<b>Management strategy</b> .....	323
<b>Application &amp; market potential</b> .....	323
<b>Biomarker analysis</b> .....	324
<i>Competitor Ratio Analysis Score = 27/40</i> .....	324
<b>Roche Diagnostics</b> .....	325
<b>Biomarker novelty &amp; technology platform</b> .....	325
<i>Figure 20: Roche's technologies for biomarker discovery and development</i> .....	325
<b>Association studies/clinical data</b> .....	325
<i>Figure 21: Roche's clinical trial programme for cardiac biomarker NT-proBNP</i> .....	326
<b>Management strategy</b> .....	326
<b>Application &amp; market potential</b> .....	326
<b>Biomarker analysis</b> .....	327
<b>Siemens Medical Solutions</b> .....	328
<b>Biomarker novelty &amp; technology platform</b> .....	328
<i>Figure 22: Siemens Integrated in vivo &amp; in vitro diagnostic suites</i> .....	328
<b>Association studies/clinical data</b> .....	328
<b>Management strategy</b> .....	329
<b>Application &amp; market potential</b> .....	329
<b>Biomarker analysis</b> .....	329
<b>Singulex</b> .....	330
<b>Biomarker novelty &amp; technology platform</b> .....	330
<i>Figure 23: Sensitivity of Singulex's Erenna system compared to ELISA and bead-based fluorescence readout systems</i> .....	330
<b>Association studies/clinical data</b> .....	330
<b>Management strategy</b> .....	331
<b>Application &amp; market potential</b> .....	331
<b>Biomarker analysis</b> .....	331
<b>SuperArray Bioscience Corporation</b> .....	332
<b>Biomarker novelty &amp; technology platform</b> .....	332
<b>Association studies/clinical data</b> .....	332
<b>Management strategy</b> .....	332
<b>Application &amp; market potential</b> .....	332
<b>Biomarker analysis</b> .....	333
<b>Vermillion</b> .....	334
<b>Biomarker novelty &amp; technology platform</b> .....	334
<b>Association studies/clinical data</b> .....	334
<b>Management strategy</b> .....	334
<b>Application &amp; market potential</b> .....	335
<b>Biomarker analysis</b> .....	335
<b>Zora Biosciences OY</b> .....	336
<b>Biomarker novelty &amp; technology platform</b> .....	336
<i>Table 8: Zora metabolite profiling platform</i> .....	336
<b>Association studies/clinical data</b> .....	336
<b>Management strategy</b> .....	336
<b>Application &amp; market potential</b> .....	336

<b>Biomarker analysis .....</b>	<b>337</b>
<b>CARDIOVASCULAR BIOMARKER APPENDIX 1 .....</b>	<b>338</b>
<i>Table 9: Global biomarker sales 2007-20015E.....</i>	<i>338</i>
<b>CARDIOVASCULAR BIOMARKER APPENDIX 2 .....</b>	<b>339</b>
<i>Table 10: Global cardiovascular biomarker sales 2007-20015E.....</i>	<i>339</i>
<b>CARDIOVASCULAR BIOMARKER APPENDIX 3 .....</b>	<b>340</b>
<b>Company Analysis Criteria .....</b>	<b>340</b>
<b>Biomarker technology &amp; platforms.....</b>	<b>340</b>
<b>Association studies .....</b>	<b>340</b>
<b>Management strategy .....</b>	<b>340</b>
<b>Application &amp; potential.....</b>	<b>340</b>
<i>Table 9: Key cardiovascular biomarker companies.....</i>	<i>341</i>
<i>Figure 26: Leading Cardiovascular Biomarker Companies – Service providers, Technology Providers, Biomarker Discovery &amp; Diagnostic Developers .....</i>	<i>343</i>
<b>GLOSSARY .....</b>	<b>344</b>
<b>ACRONYMS.....</b>	<b>346</b>
<b>BIBLIOGRAPHY &amp; ENDNOTES.....</b>	<b>350</b>